Harmful and beneficial effects of inflammation after spinal cord injury. potential therapeutic implications

Handbook of Clinical Neurology

Volumn 109, Issue , 2012, Pages 485-502

  David, Samuel ^a   López Vales, Rubèn ^a   Wee Yong, V ^b  

^a RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84867765161     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-444-52137-8.00030-9     Document Type: Chapter

References (163)

1. Abraham K.E., McMillen D., Brewer K.L. The effects of endogenous interleukin-10 on gray matter damage and the development of pain behaviors following excitotoxic spinal cord injury in the mouse. Neuroscience 2004, 124:945-952.
2. Akassoglou K., Bauer J., Kassiotis G., et al. Oligodendrocyte apoptosis and primary demyelination induced by local TNF/p55TNF receptor signaling in the central nervous system of transgenic mice: models for multiple sclerosis with primary oligodendrogliopathy. Am J Pathol 1998, 153:801-813.
3. Akdemir O., Berksoy I., Karaoglan A., et al. Therapeutic efficacy of Ac-DMQD-CHO, a caspase 3 inhibitor, for rat spinal cord injury. J Clin Neurosci 2008, 15:672-678.
4. Alexander J.J., Anderson A.J., Barnum S.R., et al. The complement cascade: Yin-Yang in neuroinflammation - neuro-protection and -degeneration. J Neurochem 2008, 107:1169-1187.
5. Anderson A.J., Robert S., Huang W., et al. Activation of complement pathways after contusion-induced spinal cord injury. J Neurotrauma 2004, 21:1831-1846.
6. Ankeny D.P., Lucin K.M., Sanders V.M., et al. Spinal cord injury triggers systemic autoimmunity: evidence for chronic B lymphocyte activation and lupus-like autoantibody synthesis. J Neurochem 2006, 99:1073-1087.
7. Bailey S.L., Carpentier P.A., McMahon E.J., et al. Innate and adaptive immune responses of the central nervous system. Crit Rev Immunol 2006, 26:149-188.
8. Bao F., Chen Y., Dekaban G.A., et al. Early anti-inflammatory treatment reduces lipid peroxidation and protein nitration after spinal cord injury in rats. J Neurochem 2004, 88:1335-1344.
9. Bao F., Chen Y., Dekaban G.A., et al. An anti-CD11d integrin antibody reduces cyclooxygenase-2 expression and protein and DNA oxidation after spinal cord injury in rats. J Neurochem 2004, 90:1194-1204.
10. Bao F., Dekaban G.A., Weaver L.C. Anti-CD11d antibody treatment reduces free radical formation and cell death in the injured spinal cord of rats. J Neurochem 2005, 94:1361-1373.
11. Bao F., Chen Y., Schneider K.A., et al. An integrin inhibiting molecule decreases oxidative damage and improves neurological function after spinal cord injury. Exp Neurol 2008, 214:160-167.
12. Bartholdi D., Schwab M.E. Expression of pro-inflammatory cytokine and chemokine mRNA upon experimental spinal cord injury in mouse: an in situ hybridization study. Eur J Neurosci 1997, 9:1422-1438.
13. Barut S., Unlu Y.A., Karaoglan A., et al. The neuroprotective effects of z-DEVD.fmk, a caspase-3 inhibitor, on traumatic spinal cord injury in rats. Surg Neurol 2005, 64:213-220. discussion 220.
14. Bavetta S., Hamlyn P.J., Burnstock G., et al. The effects of FK506 on dorsal column axons following spinal cord injury in adult rats: neuroprotection and local regeneration. Exp Neurol 1999, 158:382-393.
15. Be'eri H., Reichert F., Saada A., et al. The cytokine network of wallerian degeneration: IL-10 and GM-CSF. Eur J Neurosci 1998, 10:2707-2713.
16. Beattie M.S., Hermann G.E., Rogers R.C., et al. Cell death in models of spinal cord injury. Prog Brain Res 2002, 137:37-47.
17. Bethea J.R., Nagashima H., Acosta M.C., et al. Systemically administered interleukin-10 reduces tumor necrosis factor-alpha production and significantly improves functional recovery following traumatic spinal cord injury in rats. J Neurotrauma 1999, 16:851-863.
18. Bouhy D., Malgrange B., Multon S., et al. Delayed GM-CSF treatment stimulates axonal regeneration and functional recovery in paraplegic rats via an increased BDNF expression by endogenous macrophages. FASEB J 2006, 20:1239-1241.
19. Bouhy D., Ghasemlou N., Lively S., Redensek A., et al. Inhibition of the Ca(2)(+)-dependent K(+) channel, KCNN4/KCa3.1, improves tissue protection and locomotor recovery after spinal cord injury. J Neurosci 2011, 31:16298-16308.
20. Boven L.A., Van Meurs M., Van Zwam M., et al. Myelin-laden macrophages are anti-inflammatory, consistent with foam cells in multiple sclerosis. Brain 2006, 129:517-526.
21. Brambilla R., Bracchi-Ricard V., Hu W.H., et al. Inhibition of astroglial nuclear factor kappaB reduces inflammation and improves functional recovery after spinal cord injury. J Exp Med 2005, 202:145-156.
22. Bredt D.S., Snyder S.H. Isolation of nitric oxide synthetase, a calmodulin-requiring enzyme. Proc Natl Acad Sci U S A 1990, 87:682-685.
23. Bruck W. The role of macrophages in Wallerian degeneration. Brain Pathol 1997, 7:741-752.
24. Brundula V., Rewcastle N.B., Metz L.M., et al. Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis. Brain 2002, 125:1297-1308.
25. Bunge R.P., Puckett W.R., Becerra J.L., et al. Observations on the pathology of human spinal cord injury. A review and classification of 22 new cases with details from a case of chronic cord compression with extensive focal demyelination. Adv Neurol 1993, 59:75-89.
26. Campbell D.S., Holt C.E. Apoptotic pathway and MAPKs differentially regulate chemotropic responses of retinal growth cones. Neuron 2003, 37:939-952.
27. Casha S., Zygun D., McGowan M.D., Bains I., et al. Results of a phase II placebo-controlled randomized trial of minocycline in acute spinal cord injury. Brain 2012, 135:1224-1236.
28. Chatzipanteli K., Garcia R., Marcillo A.E., et al. Temporal and segmental distribution of constitutive and inducible nitric oxide synthases after traumatic spinal cord injury: effect of aminoguanidine treatment. J Neurotrauma 2002, 19:639-651.
29. Choi Y., Kim H.S., Shin K.Y., et al. Minocycline attenuates neuronal cell death and improves cognitive impairment in Alzheimer's disease models. Neuropsychopharmacology 2007, 32:2393-2404.
30. Cockroft K.M., Meistrell M., Zimmerman G.A., et al. Cerebroprotective effects of aminoguanidine in a rodent model of stroke. Stroke 1996, 27:1393-1398.
31. Colak A., Karaoglan A., Barut S., et al. Neuroprotection and functional recovery after application of the caspase-9 inhibitor z-LEHD-fmk in a rat model of traumatic spinal cord injury. J Neurosurg Spine 2005, 2:327-334.
32. Crane I.J., Liversidge J. Mechanisms of leukocyte migration across the blood-retina barrier. Springer Semin Immunopathol 2008, 30:165-177.
33. Crowe M.J., Bresnahan J.C., Shuman S.L., et al. Apoptosis and delayed degeneration after spinal cord injury in rats and monkeys. Nat Med 1997, 3:73-76.
34. Cuzzocrea S., Genovese T., Mazzon E., et al. Effect of 17beta-estradiol on signal transduction pathways and secondary damage in experimental spinal cord trauma. Shock 2008, 29:362-371.
35. David S., Lacroix S. Molecular approaches to spinal cord repair. Annu Rev Neurosci 2003, 26:411-440.
36. David S., Bouchard C., Tsatas O., et al. Macrophages can modify the nonpermissive nature of the adult mammalian central nervous system. Neuron 1990, 5:463-469.
37. Demjen D., Klussmann S., Kleber S., et al. Neutralization of CD95 ligand promotes regeneration and functional recovery after spinal cord injury. Nat Med 2004, 10:389-395.
38. Dergham P., Ellezam B., Essagian C., et al. Rho signaling pathway targeted to promote spinal cord repair. J Neurosci 2002, 22:6570-6577.
39. Diab A., Deng C., Smith J.D., et al. Peroxisome proliferator-activated receptor-gamma agonist 15-deoxy-Delta(12,14)-prostaglandin J(2) ameliorates experimental autoimmune encephalomyelitis. J Immunol 2002, 168:2508-2515.
40. Diaz-Ruiz A., Ibarra A., Perez-Severiano F., et al. Constitutive and inducible nitric oxide synthase activities after spinal cord contusion in rats. Neurosci Lett 2002, 319:129-132.
41. Dinomais M., Stana L., Egon G., et al. Significant recovery of motor function in a patient with complete T7 paraplegia receiving etanercept. J Rehabil Med 2009, 41:286-288.
42. Donnelly D.J., Popovich P.G. Inflammation and its role in neuroprotection, axonal regeneration and functional recovery after spinal cord injury. Exp Neurol 2008, 209:378-388.
43. Dubreuil C.I., Winton M.J., McKerracher L. Rho activation patterns after spinal cord injury and the role of activated Rho in apoptosis in the central nervous system. J Cell Biol 2003, 162:233-243.
44. Eng L.F., Lee Y.L. Response of chemokine antagonists to inflammation in injured spinal cord. Neurochem Res 2003, 28:95-100.
45. Fehlings M.G., Tator C.H. The effect of direct current field polarity on recovery after acute experimental spinal cord injury. Brain Res 1992, 579:32-42.
46. Fehlings M.G., Theodore N., Harrop J., Maurais G., et al. A phase I/IIa clinical trial of a recombinant Rho protein antagonist in acute spinal cord injury. J Neurotrauma 2011, 28:787-796.
47. Fenyk-Melody J.E., Garrison A.E., Brunnert S.R., et al. Experimental autoimmune encephalomyelitis is exacerbated in mice lacking the NOS2 gene. J Immunol 1998, 160:2940-2946.
48. Ferguson A.R., Christensen R.N., Gensel J.C., et al. Cell death after spinal cord injury is exacerbated by rapid TNF alpha-induced trafficking of GluR2-lacking AMPARs to the plasma membrane. J Neurosci 2008, 28:11391-11400.
49. Fischer D., Hauk T.G., Muller A., et al. Crystallins of the beta/gamma-superfamily mimic the effects of lens injury and promote axon regeneration. Mol Cell Neurosci 2008, 37:471-479.
50. Fleming J.C., Norenberg M.D., Ramsay D.A., et al. The cellular inflammatory response in human spinal cords after injury. Brain 2006, 129:3249-3269.
51. Fleming J.C., Bao F., Chen Y., et al. Alpha4beta1 integrin blockade after spinal cord injury decreases damage and improves neurological function. Exp Neurol 2008, 214:147-159.
52. Fordyce C.B., Jagasia R., Zhu X., et al. Microglia Kv1.3 channels contribute to their ability to kill neurons. J Neurosci 2005, 25:7139-7149.
53. Fournier A.E., Takizawa B.T., Strittmatter S.M. Rho kinase inhibition enhances axonal regeneration in the injured CNS. J Neurosci 2003, 23:1416-1423.
54. Franson P., Ronnevi L.O. Myelin breakdown and elimination in the posterior funiculus of the adult cat after dorsal rhizotomy: a light and electron microscopic qualitative and quantitative study. J Comp Neurol 1984, 223:138-151.
55. Fry E.J., Ho C., David S. A role for Nogo receptor in macrophage clearance from injured peripheral nerve. Neuron 2007, 53:649-662.
56. Galvan M.D., Luchetti S., Burgos A.M., et al. Deficiency in complement C1q improves histological and functional locomotor outcome after spinal cord injury. J Neurosci 2008, 28:13876-13888.
57. Genovese T., Mazzon E., Crisafulli C., et al. Immunomodulatory effects of etanercept in an experimental model of spinal cord injury. J Pharmacol Exp Ther 2006, 316:1006-1016.
58. Genovese T., Mazzon E., Crisafulli C., et al. TNF-alpha blockage in a mouse model of SCI: evidence for improved outcome. Shock 2008, 29:32-41.
59. Genovese T., Esposito E., Mazzon E., et al. Absence of endogenous interleukin-10 enhances secondary inflammatory process after spinal cord compression injury in mice. J Neurochem 2009, 108:1360-1372.
60. George R., Griffin J.W. Delayed macrophage responses and myelin clearance during Wallerian degeneration in the central nervous system: the dorsal radiculotomy model. Exp Neurol 1994, 129:225-236.
61. Ghasemlou N., Kerr B.J., David S. Tissue displacement and impact force are important contributors to outcome after spinal cord contusion injury. Exp Neurol 2005, 196:9-17.
62. Ghirnikar R.S., Lee Y.L., Eng L.F. Chemokine antagonist infusion attenuates cellular infiltration following spinal cord contusion injury in rat. J Neurosci Res 2000, 59:63-73.
63. Glaser J., Gonzalez R., Perreau V.M., et al. Neutralization of the chemokine CXCL10 enhances tissue sparing and angiogenesis following spinal cord injury. J Neurosci Res 2004, 77:701-708.
64. Glaser J., Gonzalez R., Sadr E., et al. Neutralization of the chemokine CXCL10 reduces apoptosis and increases axon sprouting after spinal cord injury. J Neurosci Res 2006, 84:724-734.
65. Gonzalez R., Hickey M.J., Espinosa J.M., et al. Therapeutic neutralization of CXCL10 decreases secondary degeneration and functional deficit after spinal cord injury in mice. Regen Med 2007, 2:771-783.
66. Gordon P.H., Moore D.H., Miller R.G., et al. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol 2007, 6:1045-1053.
67. Gris D., Marsh D.R., Oatway M.A., et al. Transient blockade of the CD11d/CD18 integrin reduces secondary damage after spinal cord injury, improving sensory, autonomic, and motor function. J Neurosci 2004, 24:4043-4051.
68. Gross S.S., Wolin M.S. Nitric oxide: pathophysiological mechanisms. Annu Rev Physiol 1995, 57:737-769.
69. Hallenbeck J.M. The many faces of tumor necrosis factor in stroke. Nat Med 2002, 8:1363-1368.
70. Hevel J.M., White K.A., Marletta M.A. Purification of the inducible murine macrophage nitric oxide synthase. Identification as a flavoprotein. J Biol Chem 1991, 266:22789-22791.
71. Huang W.L., King V.R., Curran O.E., et al. A combination of intravenous and dietary docosahexaenoic acid significantly improves outcome after spinal cord injury. Brain 2007, 130:3004-3019.
72. Huang X., Choi J.K., Park S.R., et al. GM-CSF inhibits apoptosis of neural cells via regulating the expression of apoptosis-related proteins. Neurosci Res 2007, 58:50-57.
73. Huang X., Kim J.M., Kong T.H., et al. GM-CSF inhibits glial scar formation and shows long-term protective effect after spinal cord injury. J Neurol Sci 2009, 277:87-97.
74. Hurlbert R.J. Methylprednisolone for acute spinal cord injury: an inappropriate standard of care. J Neurosurg 2000, 93:1-7.
75. Hurlbert R.J. Strategies of medical intervention in the management of acute spinal cord injury. Spine 2006, 31:S16-S21. discussion S36.
76. Hurlbert R.J., Hamilton M.G. Methylprednisolone for acute spinal cord injury: 5-year practice reversal. Can J Neurol Sci 2008, 35:41-45.
77. Iadecola C. Bright and dark sides of nitric oxide in ischemic brain injury. Trends Neurosci 1997, 20:132-139.
78. Iadecola C., Zhang F., Xu S., et al. Inducible nitric oxide synthase gene expression in brain following cerebral ischemia. J Cereb Blood Flow Metab 1995, 15:378-384.
79. Jakeman L.B., Guan Z., Wei P., et al. Traumatic spinal cord injury produced by controlled contusion in mouse. J Neurotrauma 2000, 17:299-319.
80. Kakulas B.A. Neuropathology: the foundation for new treatments in spinal cord injury. Spinal Cord 2004, 42:549-563.
81. Kalyvas A., Baskakis C., Magrioti V., et al. Differing roles for members of the phospholipase A2 superfamily in experimental autoimmune encephalomyelitis. Brain 2009, 132:1221-1235.
82. Kaushal V., Schlichter L.C. Mechanisms of microglia-mediated neurotoxicity in a new model of the stroke penumbra. J Neurosci 2008, 28:2221-2230.
83. Kaushal V., Koeberle P.D., Wang Y., et al. The Ca2+-activated K+ channel KCNN4/KCa3.1 contributes to microglia activation and nitric oxide-dependent neurodegeneration. J Neurosci 2007, 27:234-244.
84. Kerr B.J., Girolami E.I., Ghasemlou N., et al. The protective effects of 15-deoxy-delta-(12,14)-prostaglandin J2 in spinal cord injury. Glia 2008, 56:436-448.
85. Kigerl K.A., McGaughy V.M., Popovich P.G. Comparative analysis of lesion development and intraspinal inflammation in four strains of mice following spinal contusion injury. J Comp Neurol 2006, 494:578-594.
86. Kim G.M., Xu J., Xu J., et al. Tumor necrosis factor receptor deletion reduces nuclear factor-kappaB activation, cellular inhibitor of apoptosis protein 2 expression, and functional recovery after traumatic spinal cord injury. J Neurosci 2001, 21:6617-6625.
87. Kunz A., Park L., Abe T., et al. Neurovascular protection by ischemic tolerance: role of nitric oxide and reactive oxygen species. J Neurosci 2007, 27:7083-7093.
88. Lambert C., Desbarats J., Arbour N., et al. Dendritic cell differentiation signals induce anti-inflammatory properties in human adult microglia. J Immunol 2008, 181:8288-8297.
89. Lawrence C.B., Allan S.M., Rothwell N.J. Interleukin-1beta and the interleukin-1 receptor antagonist act in the striatum to modify excitotoxic brain damage in the rat. Eur J Neurosci 1998, 10:1188-1195.
90. Lee Y.L., Shih K., Bao P., et al. Cytokine chemokine expression in contused rat spinal cord. Neurochem Int 2000, 36:417-425.
91. Leon S., Yin Y., Nguyen J., et al. Lens injury stimulates axon regeneration in the mature rat optic nerve. J Neurosci 2000, 20:4615-4626.
92. Li M., Ona V.O., Chen M., et al. Functional role and therapeutic implications of neuronal caspase-1 and -3 in a mouse model of traumatic spinal cord injury. Neuroscience 2000, 99:333-342.
93. Liu K.M., Shen C.L. Ultrastructural sequence of myelin breakdown during Wallerian degeneration in the rat optic nerve. Cell Tissue Res 1985, 242:245-256.
94. Loddick S.A., Rothwell N.J. Neuroprotective effects of human recombinant interleukin-1 receptor antagonist in focal cerebral ischaemia in the rat. J Cereb Blood Flow Metab 1996, 16:932-940.
95. López-Vales R., Garcia-Alias G., Fores J., et al. FK 506 reduces tissue damage and prevents functional deficit after spinal cord injury in the rat. J Neurosci Res 2005, 81:827-836.
96. López-Vales R., Garcia-Alias G., Guzman-Lenis M.S., et al. Effects of COX-2 and iNOS inhibitors alone or in combination with olfactory ensheathing cell grafts after spinal cord injury. Spine 2006, 31:1100-1106.
97. López-Vales R., Navarro X., Shimizu T., et al. Intracellular phospholipase A(2) group IVA and group VIA play important roles in Wallerian degeneration and axon regeneration after peripheral nerve injury. Brain 2008, 131:2620-2631.
98. López-Vales R., Ghasemlou N., Redensek A., Kerr B.J., et al. Phospholipase A2 superfamily members play divergent roles after spinal cord injury. FASEB J. 2011, 25:4240-4252.
99. Lord-Fontaine S., Yang F., Diep Q., et al. Local inhibition of Rho signaling by cell-permeable recombinant protein BA-210 prevents secondary damage and promotes functional recovery following acute spinal cord injury. J Neurotrauma 2008, 25:1309-1322.
100. Ma M., Wei T., Boring L., et al. Monocyte recruitment and myelin removal are delayed following spinal cord injury in mice with CCR2 chemokine receptor deletion. J Neurosci Res 2002, 68:691-702.
101. Madsen J.R., MacDonald P., Irwin N., et al. Tacrolimus (FK506) increases neuronal expression of GAP-43 and improves functional recovery after spinal cord injury in rats. Exp Neurol 1998, 154:673-683.
102. Malipiero U.V., Frei K., Fontana A. Production of hemopoietic colony-stimulating factors by astrocytes. J Immunol 1990, 144:3816-3821.
103. Matis G.K., Birbilis T.A. Erythropoietin in spinal cord injury. Eur Spine J 2009, 18:314-323.
104. McKerracher L., David S. Easing the brakes on spinal cord repair. Nat Med 2004, 10:1052-1053.
105. Metz L.M., Zhang Y., Yeung M., et al. Minocycline reduces gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis. Ann Neurol 2004, 55:756.
106. Moncada S., Higgs E.A. Endogenous nitric oxide: physiology, pathology and clinical relevance. Eur J Clin Invest 1991, 21:361-374.
107. Muller A., Hauk T.G., Fischer D. Astrocyte-derived CNTF switches mature RGCs to a regenerative state following inflammatory stimulation. Brain 2007, 130:3308-3320.
108. Muppidi J.R., Siegel R.M. Ligand-independent redistribution of Fas (CD95) into lipid rafts mediates clonotypic T cell death. Nat Immunol 2004, 5:182-189.
109. Naruo S., Okajima K., Taoka Y., et al. Prostaglandin E1 reduces compression trauma-induced spinal cord injury in rats mainly by inhibiting neutrophil activation. J Neurotrauma 2003, 20:221-228.
110. Nesic O., Xu G.Y., McAdoo D., et al. IL-1 receptor antagonist prevents apoptosis and caspase-3 activation after spinal cord injury. J Neurotrauma 2001, 18:947-956.
111. Nicholson D.W. From bench to clinic with apoptosis-based therapeutic agents. Nature 2000, 407:810-816.
112. Norenberg M.D., Smith J., Marcillo A. The pathology of human spinal cord injury: defining the problems. J Neurotrauma 2004, 21:429-440.
113. Oatway M.A., Chen Y., Bruce J.C., et al. Anti-CD11d integrin antibody treatment restores normal serotonergic projections to the dorsal, intermediate, and ventral horns of the injured spinal cord. J Neurosci 2005, 25:637-647.
114. Ousman S.S., David S. MIP-1alpha, MCP-1, GM-CSF, and TNF-alpha control the immune cell response that mediates rapid phagocytosis of myelin from the adult mouse spinal cord. J Neurosci 2001, 21:4649-4656.
115. Ozawa H., Keane R.W., Marcillo A.E., et al. Therapeutic strategies targeting caspase inhibition following spinal cord injury in rats. Exp Neurol 2002, 177:306-313.
116. Pan J.Z., Ni L., Sodhi A., et al. Cytokine activity contributes to induction of inflammatory cytokine mRNAs in spinal cord following contusion. J Neurosci Res 2002, 68:315-322.
117. Park S.W., Yi J.H., Miranpuri G., et al. Thiazolidinedione class of peroxisome proliferator-activated receptor gamma agonists prevents neuronal damage, motor dysfunction, myelin loss, neuropathic pain, and inflammation after spinal cord injury in adult rats. J Pharmacol Exp Ther 2007, 320:1002-1012.
118. Pearse D.D., Chatzipanteli K., Marcillo A.E., et al. Comparison of iNOS inhibition by antisense and pharmacological inhibitors after spinal cord injury. J Neuropathol Exp Neurol 2003, 62:1096-1107.
119. Pereira M.P., Hurtado O., Cardenas A., et al. Rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2 cause potent neuroprotection after experimental stroke through noncompletely overlapping mechanisms. J Cereb Blood Flow Metab 2006, 26:218-229.
120. Perrin F.E., Lacroix S., Aviles-Trigueros M., et al. Involvement of monocyte chemoattractant protein-1, macrophage inflammatory protein-1alpha and interleukin-1beta in Wallerian degeneration. Brain 2005, 128:854-866.
121. Pineau I., Lacroix S. Proinflammatory cytokine synthesis in the injured mouse spinal cord: multiphasic expression pattern and identification of the cell types involved. J Comp Neurol 2007, 500:267-285.
122. Plunkett J.A., Yu C.G., Easton J.M., et al. Effects of interleukin-10 (IL-10) on pain behavior and gene expression following excitotoxic spinal cord injury in the rat. Exp Neurol 2001, 168:144-154.
123. Popovich P.G., Longbrake E.E. Can the immune system be harnessed to repair the CNS?. Nat Rev Neurosci 2008, 9:481-493.
124. Popovich P.G., Guan Z., Wei P., et al. Depletion of hematogenous macrophages promotes partial hindlimb recovery and neuroanatomical repair after experimental spinal cord injury. Exp Neurol 1999, 158:351-365.
125. Probert L., Eugster H.P., Akassoglou K., et al. TNFR1 signalling is critical for the development of demyelination and the limitation of T-cell responses during immune-mediated CNS disease. Brain 2000, 123:2005-2019.
126. Puckett W.R., Hiester E.D., Norenberg M.D., et al. The astroglial response to Wallerian degeneration after spinal cord injury in humans. Exp Neurol 1997, 148:424-432.
127. Qiao F., Atkinson C., Song H., et al. Complement plays an important role in spinal cord injury and represents a therapeutic target for improving recovery following trauma. Am J Pathol 2006, 169:1039-1047.
128. Rebhun J., Madorsky J.G., Glovsky M.M. Proteins of the complement system and acute phase reactants in sera of patients with spinal cord injury. Ann Allergy 1991, 66:335-338.
129. Relton J.K., Martin D., Thompson R.C., et al. Peripheral administration of interleukin-1 receptor antagonist inhibits brain damage after focal cerebral ischemia in the rat. Exp Neurol 1996, 138:206-213.
130. Resnick D.K., Graham S.H., Dixon C.E., et al. Role of cyclooxygenase 2 in acute spinal cord injury. J Neurotrauma 1998, 15:1005-1013.
131. Rice T., Larsen J., Rivest S., et al. Characterization of the early neuroinflammation after spinal cord injury in mice. J Neuropathol Exp Neurol 2007, 66:184-195.
132. Saada A., Reichert F., Rotshenker S. Granulocyte macrophage colony stimulating factor produced in lesioned peripheral nerves induces the up-regulation of cell surface expression of MAC-2 by macrophages and Schwann cells. J Cell Biol 1996, 133:159-167.
133. Sahrbacher U.C., Lechner F., Eugster H.P., et al. Mice with an inactivation of the inducible nitric oxide synthase gene are susceptible to experimental autoimmune encephalomyelitis. Eur J Immunol 1998, 28:1332-1338.
134. Schwab J.M., Conrad S., Elbert T., et al. Lesional RhoA+ cell numbers are suppressed by anti-inflammatory, cyclooxygenase-inhibiting treatment following subacute spinal cord injury. Glia 2004, 47:377-386.
135. Schwab J.M., Chiang N., Arita M., et al. Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature 2007, 447:869-874.
136. Schwartz M., Yoles E. Immune-based therapy for spinal cord repair: autologous macrophages and beyond. J Neurotrauma 2006, 23:360-370.
137. Schwartz M., Moalem G., Leibowitz-Amit R., et al. Innate and adaptive immune responses can be beneficial for CNS repair. Trends Neurosci 1999, 22:295-299.
138. Serhan C.N., Yacoubian S., Yang R. Anti-inflammatory and proresolving lipid mediators. Annu Rev Pathol 2008, 3:279-312.
139. Sinz E.H., Kochanek P.M., Dixon C.E., et al. Inducible nitric oxide synthase is an endogenous neuroprotectant after traumatic brain injury in rats and mice. J Clin Invest 1999, 104:647-656.
140. Springer J.E., Azbill R.D., Knapp P.E. Activation of the caspase-3 apoptotic cascade in traumatic spinal cord injury. Nat Med 1999, 5:943-946.
141. Sroga J.M., Jones T.B., Kigerl K.A., et al. Rats and mice exhibit distinct inflammatory reactions after spinal cord injury. J Comp Neurol 2003, 462:223-240.
142. Stirling D.P., Yong V.W. Dynamics of the inflammatory response after murine spinal cord injury revealed by flow cytometry. J Neurosci Res 2008, 86:1944-1958.
143. Stirling D.P., Liu S., Kubes P., et al. Depletion of Ly6G/Gr-1 leukocytes after spinal cord injury in mice alters wound healing and worsens neurological outcome. J Neurosci 2009, 29:753-764.
144. Stoll G., Trapp B.D., Griffin J.W. Macrophage function during Wallerian degeneration of rat optic nerve: clearance of degenerating myelin and Ia expression. J Neurosci 1989, 9:2327-2335.
145. Stout R.D., Suttles J. Functional plasticity of macrophages: reversible adaptation to changing microenvironments. J Leukoc Biol 2004, 76:509-513.
146. Takami T., Oudega M., Bethea J.R., et al. Methylprednisolone and interleukin-10 reduce gray matter damage in the contused Fischer rat thoracic spinal cord but do not improve functional outcome. J Neurotrauma 2002, 19:653-666.
147. Taoka Y., Okajima K., Uchiba M., et al. Role of neutrophils in spinal cord injury in the rat. Neuroscience 1997, 79:1177-1182.
148. Wells J.E., Hurlbert R.J., Fehlings M.G., et al. Neuroprotection by minocycline facilitates significant recovery from spinal cord injury in mice. Brain 2003, 126:1628-1637.
149. Wittchen E.S. Endothelial signaling in paracellular and transcellular leukocyte transmigration. Front Biosci 2009, 14:2522-2545.
150. Wrathall J.R., Pettegrew R.K., Harvey F. Spinal cord contusion in the rat: production of graded, reproducible, injury groups. Exp Neurol 1985, 88:108-122.
151. Wu D.C., Jackson-Lewis V., Vila M., et al. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci 2002, 22:1763-1771.
152. Xiong Y., Hall E.D. Pharmacological evidence for a role of peroxynitrite in the pathophysiology of spinal cord injury. Exp Neurol 2009, 216:105-114.
153. Xiong Y., Rabchevsky A.G., Hall E.D. Role of peroxynitrite in secondary oxidative damage after spinal cord injury. J Neurochem 2007, 100:639-649.
154. Xu J., Kim G.M., Chen S., et al. iNOS and nitrotyrosine expression after spinal cord injury. J Neurotrauma 2001, 18:523-532.
155. Yang L., Blumbergs P.C., Jones N.R., et al. Early expression and cellular localization of proinflammatory cytokines interleukin-1beta, interleukin-6, and tumor necrosis factor-alpha in human traumatic spinal cord injury. Spine 2004, 29:966-971.
156. Yang L., Jones N.R., Blumbergs P.C., et al. Severity-dependent expression of pro-inflammatory cytokines in traumatic spinal cord injury in the rat. J Clin Neurosci 2005, 12:276-284.
157. Yin Y., Cui Q., Li Y., et al. Macrophage-derived factors stimulate optic nerve regeneration. J Neurosci 2003, 23:2284-2293.
158. Yin Y., Henzl M.T., Lorber B., et al. Oncomodulin is a macrophage-derived signal for axon regeneration in retinal ganglion cells. Nat Neurosci 2006, 9:843-852.
159. Yoon S.H., Shim Y.S., Park Y.H., et al. Complete spinal cord injury treatment using autologous bone marrow cell transplantation and bone marrow stimulation with granulocyte macrophage-colony stimulating factor: Phase I/II clinical trial. Stem Cells 2007, 25:2066-2073.
160. Young W. Spinal cord contusion models. Prog Brain Res 2002, 137:231-255.
161. Zabad R.K., Metz L.M., Todoruk T.R., et al. The clinical response to minocycline in multiple sclerosis is accompanied by beneficial immune changes: a pilot study. Mult Scler 2007, 13:517-526.
162. Zhang F., Casey R.M., Ross M.E., et al. Aminoguanidine ameliorates and L-arginine worsens brain damage from intraluminal middle cerebral artery occlusion. Stroke 1996, 27:317-323.
163. Zhang Y., Metz L.M., Yong V.W., et al. Pilot study of minocycline in relapsing-remitting multiple sclerosis. Can J Neurol Sci 2008, 35:185-191.